{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:41:03Z","timestamp":1791200463269,"version":"4.2.0"},"publisher-location":"Berlin, Heidelberg","reference-count":20,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642279935","type":"print"},{"value":"9783642279942","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:00:00Z","timestamp":1345766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:00:00Z","timestamp":1345766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-27994-2_32","type":"book-chapter","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T01:26:30Z","timestamp":1345685190000},"page":"551-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Peptide Receptor Radionuclide Therapy with 177Lu Labeled Somatostatin Analogs DOTATATE and DOTATOC: Contrasting Renal Dosimetry in the Same Patient"],"prefix":"10.1007","author":[{"given":"Harshad R.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Schuchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,24]]},"reference":[{"key":"32_CR1","unstructured":"Arora P, Verrelli M, Mulloy LL, Talavera F, Aronoff GR, Schmidt RJ, Batuman V. Chronic Renal failure. eMedicine Medscape references Feb 2012. http:\/\/emedicine.medscape.com\/article\/238798-overview"},{"key":"32_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002590050216","volume":"25","author":"TM Behr","year":"1998","unstructured":"Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25:201\u2013212","journal-title":"Eur J Nucl Med"},{"key":"32_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","volume":"30","author":"L Bodei","year":"2003","unstructured":"Bodei L, Cremonesi M, Zoboli S (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med 30:207\u2013216","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"32_CR4","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, Pacifi C, Grana C, Bartolomei M, Baio S, Sansovini M, Paganelli G (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med 35(10):1847\u20131856","journal-title":"Eur J Nucl Med"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med 50:477\u2013484","journal-title":"J Nucl Med"},{"issue":"9","key":"32_CR6","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47(9):1467\u20131475","journal-title":"J Nucl Med"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<406::AID-IJC14>3.0.CO;2-6","volume":"75","author":"M De Jong","year":"1998","unstructured":"De Jong M, Bakker WH, Breeman WA et al (1998) Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 75:406\u2013411","journal-title":"Int J Cancer"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/snuc.2002.31027","volume":"32","author":"M De Jong","year":"2002","unstructured":"De Jong M, Valkema R, Jamar F (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133","journal-title":"Semin Nucl Med"},{"key":"32_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00259-006-0172-9","volume":"33","author":"JP Esser","year":"2006","unstructured":"Esser JP, Krenning EP, Teunissen JJM (2006) Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu-DOTA0, Tyr3] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med 33:1346\u20131351","journal-title":"Eur J Nucl Med"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00259-004-1553-6","volume":"31","author":"F Forrer","year":"2004","unstructured":"Forrer F, Uusij\u00e4rvi H, Waldherr C (2004) A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med 31:1257\u20131262","journal-title":"Eur J Nucl Med"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1007\/s00259-004-1561-6","volume":"31","author":"A Helisch","year":"2004","unstructured":"Helisch A, F\u00f6rster GJ, Reber H (2004) Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med 31:1386\u20131392","journal-title":"Eur J Nucl Med"},{"key":"32_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","volume":"30","author":"F Jamar","year":"2003","unstructured":"Jamar F, Barone R, Matthieu I et al (2003) 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487)\u2014a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regiments of amino acid coinfusion. Eur J Nucl Med 30:510","journal-title":"Eur J Nucl Med"},{"key":"32_CR13","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G (2005a) An overview of the results of peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogues. J Nucl Med 46:62S","journal-title":"J Nucl Med"},{"key":"32_CR14","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005b) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]-octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754","journal-title":"J Clin Oncol"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1667\/RR3105","volume":"161","author":"B Lambert","year":"2004","unstructured":"Lambert B, Cybulla M, Weiner SM et al (2004) Renal toxicity after radionuclide therapy. Radiat Res 161:607\u2013611","journal-title":"Radiat Res"},{"key":"32_CR16","unstructured":"National Chronic Kidney Disease Fact Sheet (2010) CDC website. http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheets\/kidney.htm"},{"key":"32_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","volume":"351","author":"A Otte","year":"1998","unstructured":"Otte A, Mueller-Brand J, Dellas S (1998) Yttrium-90 labeled somatostatin analogue for cancer treatment. Lancet 351:417","journal-title":"Lancet"},{"issue":"suppl 1","key":"32_CR18","first-page":"92S","volume":"46","author":"S Pauwels","year":"2005","unstructured":"Pauwels S, Barone R, Walrand S et al (2005) Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs. J Nucl Med 46(suppl 1):92S\u201398S","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"32_CR19","first-page":"83S","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46(suppl 1):83S\u201391S","journal-title":"J Nucl Med"},{"issue":"3","key":"32_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1089\/cbr.2006.325","volume":"22","author":"C Wehrmann","year":"2007","unstructured":"Wehrmann C, Senftleben S, Zachert C, Mueller D, Baum RP (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22(3):406\u2013416","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Recent Results in Cancer Research","Theranostics, Gallium-68, and Other Radionuclides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-27994-2_32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:56:11Z","timestamp":1676048171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-27994-2_32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,24]]},"ISBN":["9783642279935","9783642279942"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-27994-2_32","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,24]]},"assertion":[{"value":"24 August 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}